What “warnings” come with Calquence (acalabrutinib)?
Calquence’s prescribing information includes safety warnings focused on key risks seen with the class of BTK inhibitors, especially for blood-cancer patients. These warnings cover serious infections, bleeding, and atrial fibrillation/flutter, among other important adverse reactions [1][2].
What infection risks are mentioned for Calquence?
Calquence can increase the risk of serious and sometimes fatal infections. Clinicians are advised to evaluate patients for infection before starting and to monitor for signs of infection during treatment. Patients should report fever or symptoms that suggest infection promptly [1][2].
What bleeding risks should patients know?
Calquence can increase bleeding risk. The warnings advise caution in patients with bleeding disorders or those taking medicines that affect bleeding (for example, anticoagulants or antiplatelet drugs). Patients should seek medical care for unusual bleeding, blood in stool or urine, or severe bruising [1][2].
What heart rhythm warning is included (atrial fibrillation/flutter)?
Calquence may cause atrial fibrillation and atrial flutter. The prescribing information advises monitoring for symptoms such as palpitations, dizziness, shortness of breath, or fainting, and managing heart rhythm issues if they occur [1][2].
Does Calquence warn about second cancers?
The prescribing information includes warnings/precautions for the development of malignancies, including secondary cancers, during treatment. Patients should be evaluated for new symptoms or concerning findings that could suggest a cancer-related problem [1][2].
Are there other important safety precautions?
Calquence also has warnings/precautions addressing other clinically significant risks and lab abnormalities reported with acalabrutinib and the BTK inhibitor class, which can affect how clinicians monitor patients during therapy [1][2].
Where can I find the full official warning text?
You can check the complete “Warnings and Precautions” section directly in:
- the Calquence FDA label [1]
- the Calquence UK summary of product characteristics (SmPC) [2]
Which patients are most likely to run into these warnings?
The boxed/major precautions in BTK inhibitors commonly matter most for patients with:
- a history of recurrent infections or frequent healthcare exposure
- prior bleeding or concurrent blood-thinning therapy
- prior atrial fibrillation/flutter or cardiovascular disease
Your oncologist or pharmacist can map these warnings to your personal history and current medications [1][2].
---
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208644
[2] https://www.medicines.org.uk/emc/product/12308/smpc